about
Antiviral therapy for symptomatic congenital cytomegalovirus infection in neonates and infants up to 3 months of ageAntiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapyCMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant RecipientsThe DNA helicase-primase complex as a target for herpes viral infectionGanciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applicationsHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsThe dynamics of human cytomegalovirus replication in vivoAntiviral drug resistance: mechanisms and clinical implicationsPhosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirusA novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovirInhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94)Design, synthesis, and antiviral evaluation of 2-deoxy-D-ribosides of substituted benzimidazoles as potential agents for human cytomegalovirus infectionsResistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56Bench-to-bedside review: rare and common viral infections in the intensive care unit--linking pathophysiology to clinical presentationDivergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolismAntiviral drug resistance of human cytomegalovirus.Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.Resistance of human cytomegalovirus to antiviral drugs.Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsEmergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency.Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analoguesTherapeutic developments in cytomegalovirus retinitis.Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation.DNA fragments binding CTCF in vitro and in vivo are capable of blocking enhancer activity.Diagnosis and management of infectious esophagitis associated with human immunodeficiency virus infection.Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinaseCytomegalovirus treatment options in immunocompromised patients.Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.Post-transplant lymphoproliferative disorder: a review.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerasePrediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
P2860
Q24248089-6009AE4D-A527-47A2-BEB2-E01F30516BD5Q24672068-272C3150-D10A-4A39-9A7B-0F02ECA72042Q26768473-2E534D18-839C-4291-86B0-8A7DA639C820Q26849412-CF81F20C-0134-40C1-B49F-34091B646AB4Q27026675-622B2BAA-44C2-40D5-AEE3-78629D22E82BQ28069489-05DDD3C0-E698-4483-BA03-3AEA7B46E332Q28141142-CE4D1D53-D720-4839-AC89-7C4EA73BF1C5Q28282376-65A10F7D-EDA9-4D35-AFF2-45119A1189B0Q28345180-974EA211-2085-4527-8266-466628C8001FQ28348812-5483202F-8A29-4BD4-830F-29CE3FD0A99AQ28353356-283DEC73-4C9C-46B7-82C3-5957DCE819DEQ28362995-F415CCCC-BD7A-4F99-A930-7EBBA0BE65D4Q28377193-C0BFF770-EB3D-45BF-B0B8-ADBAE256AF4BQ28377197-7080501D-F004-44F6-8D80-FAA1AFFE7C6AQ28379493-D5273084-CF42-4DB1-AFE1-48AA2A26AECCQ28386164-0AE0233B-29B3-43EC-970E-52641DBFF218Q28479023-A0BB9CC2-2564-4075-BE8D-0A0AC3E074C1Q30430427-022040D2-020B-4F37-855C-737A9DEE4611Q31011523-0B9C076C-BDA0-4E8E-ADE5-DA9890D3BBA3Q33345650-3DC937E2-1B5B-416E-9772-B02E3F44A4A4Q33363887-4086EB32-FE45-4189-8887-B6BF54BEB7F8Q33588911-40FC33B6-EBCB-4AF7-A2AA-18C372242E6DQ33661417-16FB7396-3432-49DA-9749-DE72192C7C43Q33696787-9AE7A91C-5762-4AA2-A53A-C4A7A548FFA4Q33812425-CA45780D-EEC6-4F03-8A1A-1CE22C14F521Q33981473-8EC2C598-813A-4C80-8A92-F5E49D86EFC9Q33982537-1A0C126C-9225-4811-B718-34FF1D762C9DQ34074692-1D410962-00AB-4341-BFDE-71C1B13DEFB3Q34109911-065359C0-2CAC-499C-A507-033C05EDA13BQ34223098-74E49362-A31C-4A31-9886-A7CBF2CEB011Q34225764-A0A41C27-B944-469A-936A-24E6CB054A32Q34338927-60E03F04-A9BB-4F9C-823B-E6BF81811941Q34390197-2349F2C8-CA5E-4318-BD22-45246F4BADE2Q34756218-B7D603D4-8160-4558-AED0-417E4D7F6718Q34975934-7ECF6659-C347-4644-893B-E79862821717Q35079593-A810F3BB-7EE4-49E0-A95A-211B2F73B712Q35103227-19F4D9DC-8791-4926-8874-80E4B6AC21BDQ35139402-3F550333-024D-4DDF-9B20-E0A576EA8A60Q35175290-4C797B66-C0A8-47FD-9C9F-BA112DEE7D1FQ35690817-EC010136-E43C-4032-A76E-C655EDDB1FC4
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Ganciclovir.
@en
type
label
Ganciclovir.
@en
prefLabel
Ganciclovir.
@en
P1476
Ganciclovir.
@en
P2093
Crumpacker CS
P304
P356
10.1056/NEJM199609053351007
P407
P577
1996-09-01T00:00:00Z